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Introduction
The Coronavirus Disease 2019 (COVID-19), came into 
limelight in early December 2019, when some cases of 
pneumonia were reported in Wuhan, Hubei, China; whose 
cause following laboratory assessment, was found to be a 
novel strain of virus belonging to the Coronavirus family 
and was labelled SARS-CoV-2 (Severe acute respiratory 
syndrome coronavirus 2) [1]. The spread of the infection 
is a rising, rapidly advancing circumstance and due to this 
whirlwind rate of spread, COVID-19 has been pronounced 
as a global pandemic by the WHO since March 11, 2020. 
As of 23rd September, more than 31.7 million positive 
cases of COVID-19 have been reported in 217 countries 
and territories with more than 975,315 deaths. COVID-19 
targets the respiratory tract of humans and has similar 
clinical symptoms to SARS-CoV and MERS-CoV [2-4]. 
Typical symptoms experienced by COVID-19 positive 
individuals include fever, dry cough, fatigue, headache, 
vomiting, diarrhoea, shortness of breath, myalgia, acute 
respiratory distress syndrome (ARDS) related symptoms 
and shock [5-9]. Previous studies reported that the patients 
who need intensive care tend to be older in age and male, 
and about 40% have comorbid conditions, including 
diabetes, cardiac diseases, hypertension, asthma and other 
chronic illnesses such as liver or kidney disease [10, 11]. 
According to the World Health Organization, about 5% 
COVID-19 patients, who are severe or critically ill require 
admission to an intensive care unit (ICU) [12]. However, 
shortages of standard healthcare resources, especially ICU 
supports are causing the high mortality rate of critically ill 
patients.
The COVID-19 pandemic has imposed an enormous burden 
and massive challenges to the health care system, especially 
ICUs, across developed, developing and underdeveloped 
countries. Likewise, Bangladesh also falls in the category 
of unfortified countries due to its high population and 
poor health care system  [13]. In Bangladesh, current 
Objectives. This study aimed to analyze the epidemiological 
and clinical characteristics of COVID-19 cases and investigate 
risk factors including comorbidities and age in relation with 
the clinical aftermath of COVID-19 in ICU admitted cases in 
Bangladesh.
Methods. In this retrospective study, epidemiological and clini-
cal characteristics, complications, laboratory results, and clini-
cal management of the patients were studied from data obtained 
from 168 individuals diagnosed with an advanced prognosis of 
COVID-19 admitted in two hospitals in Bangladesh.
Results. Individuals in the study sample contracted COVID-19 
through community transmission. 56.5% (n = 95) cases died in 
intensive care units (ICU) during the study period. The median 
age was 56 years and 79.2% (n = 134) were male. Typical clini-
cal manifestation included Acute respiratory distress syndrome 
(ARDS) related complications (79.2%), fever (54.2%) and cough 
(25.6%) while diabetes mellitus (52.4%), hypertension (41.1%) 
and heart diseases (16.7%) were the conventional comorbidi-
ties. Clinical outcomes were detrimental due to comorbidities 
rather than age and comorbid individuals over 50 were at more 
risk. In the sample, oxygen saturation was low (< 95% SpO2) 
in 135 patients (80.4%) and 158 (93.4%) patients received sup-
plemental oxygen. Identical biochemical parameters were found 
in both deceased and surviving cases. Administration of anti-
viral drug Remdesivir and the glucocorticoid, Dexamethasone 
increased the proportion of surviving patients slightly. 
Conclusions. Susceptibility to developing critical illness due to 
COVID-19 was found more in comorbid males. These atypical 
patients require more clinical attention from the prospect of con-
trolling mortality rate in Bangladesh. 
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median age is 26.7 years and mortality rate is 5.52 [14]. 
Moreover, life expectancy is 73.4 years and a total of 7% 
of the county’s population are senior citizens [14, 15]. Most 
of these senior citizens, as well as middle-aged people in 
the country, have comorbidities, such as diabetes (9.7%), 
asthma (5.2%), hypertension (20%), cardiac disease (4.5%) 
and chronic pulmonary disease (11.9%), and around 1.3 to 
1.5 million cancer patients in the country are vulnerable to 
COVID-19 [16-19]. All of these people, who belong to a 
vulnerable group, may require immediate hospitalisation 
and intensive care if they contract COVID-19  [11]. 
Compared to the eight worst affected countries, Bangladesh 
has the lowest number of COVID-19 ICU beds per 
10,000 inhabitants (Supplementary Fig. 1). How the health 
management system with its poor and limited resources is 
responding to and tackling critical COVID-19 patients is 
a matter of inordinate concern. Therefore, it is important 
for health and government authorities to have information 
on the clinical features and outcomes of COVID-19 in 
critically ill cases for them to address the necessities of 
ICU facilities and prepare for a possible second wave of 
COVID-19 in Bangladesh. In China, India, Greece and 
the U.S., similar epidemiological studies have already 
been conducted sampling COVID-19 patients admitted 
in the ICU, in order to distinguish COVID-19’s clinical 
implications on patients who had to be admitted in the ICU. 
Insights obtained from these studies can assist experts to 
further pinpoint exact management and follow-up medical 
routines [20-23]. Therefore, this study aims to investigate 
the epidemiological and clinical features, disease severity, 
treatment and clinical outcomes of critical COVID-19 
cases in Bangladesh with the goal of portraying a bigger 
picture of severe clinical manifestations of COVID-19 so 
that the malleability Bangladesh’s health care system can 
be modified in terms of tackling COVID-19.
Methods
Patients and data collection
This study’s sample comprises 168 COVID-19 patients 
with definite outcomes who were admitted to Chittagong 
General Hospital and Chittagong Medical College 
Hospital (COVID-19 unit) between 1st April 2020 and 
7th August 2020. The Chittagong General Hospital and 
Chittagong Medical College Hospital (COVID-19 unit) 
are specialised hospitals that have been authorised for 
managing most of the critical COVID-19 patients in the 
country’s economic hub, namely Chattogram city. The 
epidemiological and demographic data for this study were 
obtained from the inpatients’ files. Approval of this study 
was provided by the Institutional Review Board (IRB) of 
Chattogram General Hospital Ethics Committee. In terms 
of data collection and usage, patients and in some cases, 
their next of kin (first degree relatives) gave their accord.
The criteria for ICU admission
Management of all the COVID-19 patients admitted in the 
ICU were implemented according to the regulations set 
nationally for COVID-19 management in Bangladesh [24]. 
Based on clinical symptoms, patients were divided into 
mild, moderate, severe and critical groups. Most of the 
severe or critical patients and few moderate ill patients 
were admitted to the ICU. Those in the severe group have 
respiratory distress, i.e. a respiratory rate of  ≥  30  beats 
per minute in a resting state and an oxygen saturation 
of ≤ 92% SpO2, and those in the critical group experience 
respiratory failure, Sepsis and shock, thus requiring 
mechanical ventilation, as well as the combined failure of 
other organs, which require ICU monitoring and treatment. 
In both the hospitals combined during the study duration, a 
total of 1,835 COVID-19 patients were admitted. Of these 
1,835 patients, 168 (9.16%) had to be admitted in the ICU 
and 95 of these 168 ICU patients died. Among the patients 
who survived, 55.9% (94/168) were in critical condition, 
39.9% (67/168) were in severe condition and other 4.2% 
(7/168) were in moderate condition. The coordinative 
physicians were accountable for collecting this data from 
the patients. ARDS was defined according to the Berlin 
definition  [25], and shock was defined according to the 
sepsis-3 criteria [26].
RT-PCR assay for COVID-19 
Whether the cases of the sample were positive with 
COVID-19 was confirmed via a real-time reverse 
transcription polymerase chain reaction (RT-PCR) assay of 
respiratory tract samples. Throat swabs were collected and 
maintained in the viral transport medium. The laboratory 
test assays for COVID-19 were conducted according to 
standards set by the World Health Organisation’s (WHO). 
Upper and lower respiratory tract specimens were 
collected in order to extract SARS-CoV-2 RNA. The RNA 
was obtained and further tested by means of RT-PCR using 
the same method that was described previously [20].
Statistical analysis and plotting
Descriptive statistical analyses were performed to express 
categorical variables with numbers and proportions. These 
were then compared using a chi-square test. P values of 
less than or equal to 0.05 (two-sided) were considered 
statistically significant. R-script and GraphPad Prism 
version 7.04 was used to perform all of the statistical 
analyses and the figure plotting. Patients with at least 
one type of comorbidity were considered comorbid, and 
those with no comorbidity were considered non-comorbid 
patients.
Results
Clinical features, epidemiological features 
and vital signs examination
Among the 168 COVID-19 patients admitted in the ICU 
with a confirmed outcome, 95 (56.5%) of the severely ill 
patients died in the ICU and the remaining 73 patients 
(43.5%) were transferred to the isolation ward following 
improvement (Tab.  I). Although 66.7% of the patients 
were over 50 years old, the highest proportion (28.6%) 
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was between 51 and 60  years old. The proportion of 
male patients (79.8%) was more than female patients 
(20.2%). The COVID-19 individuals were into diverse 
professions and while the 10 (6.0%) of the patients had 
direct involvement in the healthcare system, most of the 
patients were from urban areas (65.5%). Persistence of 
a comorbidity was directly proportional to the state of 
being admitted in the ICU. As shown in Figure 1A, the 
proportion of deceased patients was relatively low in the 
group without comorbidities. Interestingly, the patients 
who were over 50 years old and had comorbidities 
comprise 66.3% of the total deaths, with the number of 
deaths being seven times the number of deaths in the 
group without comorbidities (Fig.  1B). About 82.1% 
(138/168) of patients had at least one coexisting chronic 
illness, predominantly diabetes (52.4%), hypertension 
(41.1%) or heart disease (16.7%) (Tab. I). The prevalence 
of diabetes, hypertension and heart disease in deceased 
patients was slightly higher (Fig.  1C). Interestingly, 
patients with asthma survived well compared to 
other comorbidities. The most common symptoms 
experienced by patients were ARDS (133/168; 79.2%), 
fever (91/168; 54.2%) and coughing (43/168; 25.6%) 
(Fig. 1D). The median length of hospital stay was five 
days, and the median length of ICU stay was four days 
(Fig. 1E). The average duration of stay in the ICU was 
higher in surviving patients. In surviving patients, the 
median length of hospital stay was eleven days, and the 
median length of ICU stay was six days (Fig.  1F). In 
case of the deceased population of this study, respiratory 
failure (78/95; 82.1%), diabetes mellitus related 
complications (30/95; 31.6%), pneumonia (20/95; 
21.0%), thromboembolic (4/95; 4.2%) and myocarditis 
(3/95; 7.4%) were found to be the most prevalent causes 
of death (Fig. 1G).
The body temperatures for all individuals in the study 
sample (Tab. II) were measured, and this ranged from 
98°F to 102+°F. The vital signs at admission to the ICU 
were moderate fever  ≥  99°F for 40  patients (71.1%), 
heart rate ≥ 100 beats per minute for 85 patients (51%) 
and a respiratory rate of ≥ 25 breaths per minute in 56% 
of the recorded patients (Tab. II). The patients who 
Tab. I. Demographic and baseline features of COVID-19 ICU patients.








Age (n = 168; dead = 95; alive = 73)
11-20 2/168 (1.2%) 2/95 (2.1%) 0/73 (0.0%)
14.7 0.03
21-30 11/168 (6.5%) 4/95 (4.2%) 7/73 (9.6%)
31-40 14/168 (8.3%) 4/95 (4.2%) 10/73 (13.7%)
41-50 29/168 (17.3%) 13/95 (13.7%) 16/73 (21.9%)
51-60 48/168 (28.6%) 34/95 (35.8%) 14/73 (19.1%)
61-70 36/168 (21.4%) 20/95 (21%) 16/73 (21.9%)
71-80 22/168 (13.1%) 15/95 (15.8%) 7/73 (9.6%)
80+ 6/168 (3.6%) 3/95 (3.1%) 3/73 (4.1%)
Sex (n = 168; dead = 95; alive = 73)
Male 134/168 (79.8%) 75/95 (78.9%) 59/73 (80.8%) 0.09
0.76
Female 34/168 (20.2%) 20/95 (21.0%) 14/73 (19.1%)
Dwelling place (n = 168; dead = 95; alive = 73)
Urban 110/168 (65.5%) 62/95 (65.3%) 48/73 (65.6%)
0.00 0.95Rural 58/168 (34.5%) 33/95 (34.4%) 25/73 (34.2%)
No 12/168 (7.1%) 9/95 (9.5%) 3/73 (4.1%)
Comorbidities (n = 168; dead = 95; alive = 73)
Diabetes 88/168 (52.4%) 53/95 (55.8%) 35/73 (47.9%) 1.02 0.31
Hypertension 69/168 (41.1%) 41/95 (43.2%) 28/73 (38.4%) 0.39 0.53
Heart diseases 28/168 (16.7%) 23/95 (24.2%) 5/73 (6.8%) 8.96 0.00
Other chronic diseases 16/168 (9.5%) 12/95 (12.6%) 4/73 (5.5%) 2.45 0.12
Asthma 15/168 (8.9%) 3/95 (3.2%) 12/73 (16.4%) 8.95 0.00
Kidney diseases 5/168 (3.0%) 3/95 (3.2%) 2/73 (2.7%) 0.02 0.87
Common symptoms during hospital admission (n = 168; dead = 95; alive = 73)
ARDS related 133/168 (79.2%) 81/95 (85.3%) 52/73 (71.2%) 4.93 0.03
Fever 91/168 (54.2%) 50/95 (52.6%) 41/73 (56.2%) 0.21 0.65
Others 43/168 (25.6%) 25/95 (26.3%) 18/73 (24.7%) 0.06 0.81
Cough 43/168 (25.6%) 26/95 (27.4%) 17/73 (23.3%) 0.36 0.55
Sore throat 10/168 (6.0%) 5/95 (5.3%) 5/73 (6.8%) 0.19 0.67
Hypertension 5/168 (3.0%) 3/95 (3.2%) 2/73 (2.7%) 0.02 0.87
Diarrhoea 4/168 (2.4%) 2/95 (2.1%) 2/73 (2.7%) 0.07 0.79
Vomiting 4/168 (2.4%) 4/95 (4.2%) 0/73 (0.0%) 3.15 0.08
n: number of patients.
A. SAHA ET AL.
E36
had a moderate or high fever (≥ 99°F) tended to have a 
higher mortality rate than those with a mild or no fever 
(Fig.  2A). Oxygen saturation was low (<  5%  SpO2) 
in 135 patients (80.4%) and the mortality rate of these 
patients was relatively high (Fig. 2B). The death rate of 
patients who had an abnormal heart rate and respiratory 
rate was higher (Fig. 2C). Shock occurred in 10 patients 
(5.9%), including cardiogenic shock in 5  patients 
(2.9%) and septic shock in 4 patients (2.4%) (Fig. 2D). 
Of all 168  ICU patients, seven (4.2%) were classified 
as having a hypertensive crisis. Unfortunately, none of 
these patients survived. ARDS occurred in 167 (99.4%) 
patients, with 31  patients (18.5%) having moderate 
ARDS, three patients (1.8%) having mild ARDS and 
Fig. 1. The clinical features of Bangladeshi patients infected with COVID-19 admitted to the ICU. (A) Frequency of number of comorbidities 
in patients admitted to the ICU; (B) Relationship between age and comorbidities and its frequency in patients; (C) Percentage of the occur-
rence of different comorbidities in total, dead and alive patients; (D) Percentage of the occurrence of different symptoms in total, dead and 
alive patients; (E) Boxplot of the number of days in the ICU and hospital for patients admitted to the ICU, with the boxes spanning the 25 to 
75 percentiles and the horizontal lines in the boxes representing the medians; (F) Boxplot of the number of days in the ICU and hospital for 
survived patients admitted to the ICU, with the boxes spanning the 25 to 75 percentiles and the horizontal lines in the boxes representing 
the medians;(G) Distribution of the reasons for death. ARDS: acute respiratory distress syndrome; ICU: intensive care unit.
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133 patients (79%) experiencing severe ARDS. Eighty 
three out of the 133 severe ARDS patients (62.4%) died 
(Fig. 2E).
Laboratory findings
The laboratory findings of the patients upon admission 
to the ICU are shown in Figure  2 and Table  III. 
Statistical analysis was only conducted on the patients 
whose laboratory results were available. Elevated levels 
of White Blood Cell (WBC) and Neutrophils were 
identified in 68.9% (42/61), and 66.7% (44/64) patients, 
respectively. For 71  patients who underwent tests on 
D-dimer, an excessive level was identified from 49 
(69.0%) patients, with the level higher than 5 mg/L in 
15 (21.1%) patients. Out of the 69 patients who had tests 
of Ferritin, elevated levels of Ferritin were identified 
in 53 (76.8%) patients (Tab.  III). The biochemical 
parameters of the survived and non-survived patients 
were also compared, and it was found that they were 
essentially identical (Figure 2F).
Management and medications
Oxygen therapy was administered in accordance 
with the patients’ oxygen saturation. Over 90% of the 
Fig. 2. Vital signs, risk factors and laboratory findings. (A) Distribution of the clinical outcomes (dead or alive) of the patients in the no or 
low fever (≤ 99°F) group compared to those in the moderate or high fever (> 99°F) group; (B) Distribution of the clinical outcomes (dead 
or alive) of the patients in the normal oxygen saturation (≥ 95% SpO2) group compared to those in the low oxygen saturation (< 95% SpO2) 
group; (C) Distribution of dead and alive patients according to their heart rate and respiratory rate, namely whether it was increased, normal 
or decreased, with the normal reference values being a heart rate of 60 to 100 beats per minute and a respiratory rate of 12 to 20 breaths 
per minute; (D) Pie chart of the occurrence of septic shock, cardiogenic shock and hypovolemic shock; (E) Distribution of the clinical out-
comes (dead or alive) of patients in the mild, moderate and severe ARDS groups; (F) Biochemical parameters of COVID-19 patients admitted 
to the ICU, with the normal reference values being: normal range of WBC of 4-10 × 109 per L, normal range of haemoglobin of 130-175 g 
per L, normal range of neutrophils of 1.8-6.3 × 109 per L, normal range of lymphocytes of 1.1-3.2 × 109 per L, normal range of platelets of 
125-350×109 per L, D-dimer < 0.5 µg/mL, Ferritin < 500 μg/L. ARDS: acute respiratory distress syndrome; F: Fahrenheit; ICU: intensive care 
unit; L: litre; TC: total count; WBC: white blood cell.
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patients who were admitted to the ICU (158/168; 93.6%) 
required oxygen during the disease. Of the 158 patients 
with available information, 64.8% (103/159) received 
oxygen support via a mask, and 25.2% (40/159) received 
oxygen support via a high flow nasal cannula. 
Prone positioning was implemented to enhance oxygenation 
and improve lung recruitability in some patients with severe 
ARDS (151/168; 89.9%) (Tab. IV). Convalescent plasma 
(CP) was transfused into eight patients. However, only 
three of these eight patients survived after the convalescent 
plasma transfusion. As for the medications administered, 
94 patients (56.0%) received antiviral agents, 164 patients 
(97.6%) received antimicrobial agents, 126 patients 
(75.0%) received an anti-allergic drug, 149 patients (88.7%) 
received anti-inflammatory drugs and 145 patients (86.3%) 
received vitamin and mineral supplements. Favipiravir 
(71/168; 42.3%) and Remdesivir (31/168; 18.4%) were 
the most commonly used antiviral drugs among the ICU 
patients. However, the proportion of surviving patients was 
greater in the Remdesivir cohort than the Favipiravir cohort 
(Fig.  3A). Additionally, Methylprednisolone (97/168; 
57.7%) and Dexamethasone (40/168; 23.8%) were the two 
most used glucocorticoids (Fig. 3A). Meropenem (126/168; 
76.2%) was the most commonly used antibiotic, followed 
by Ceftriaxone (50/168; 29.8%), Azithromycin (33/168; 
19.4%) and Moxifloxacin (33/168; 19.4%) (Fig. 3A).  As 
shown in Figure  3B, the proportion of survived patients 
was slightly higher with the use of Meropenem, as well 
as Remdesivir and Dexamethasone, than with the use of 
Favipiravir or Methylprednisolone. Six patients were treated 
with Remdesivir and Dexamethasone and only one of them 
died. The vitamin C, vitamin D and zinc supplements that 
were commonly used did not show any improved clinical 
outcomes (Fig. 3C).
Tab. II. Vital signs at ICU admission of COVID-19 patients.








Temperature (°F) (n = 168; dead = 95; alive = 73)
< 98.0 5/168 (3.0%) 4/95 (4.2%) 1/73 (1.4%)
7.38 0.19
98 to 99 127/168 (75.6%) 66/95 (69.5%) 61/73 (83.5%)
99.1 to 100 31/168 (18.4%) 21/95 (22.1%) 10/73 (13.7%)
100.1 to 102 3/168 (1.8%) 2/95 (2.1%) 1/73 (1.4%)
102+ 2/168 (1.2%) 2/95 (2.1%) 0/73 (0.0%)
Heart rate (normal: 60 to 100 beats per minute) (n = 168; dead = 95; alive = 73)
Increased 85/168 (50.6%) 53/95 (55.8%) 32/73 (43.8%)
4.28 0.12Normal 68/168 (40.5%) 32/95 (33.7%) 36/73 (49.3%)
Decreased 15/168 (8.9%) 10/95 (10.5%) 5/73 (6.9%)
Respiratory rate (normal: 12 to 20 breaths per minute) (n = 168; dead = 95; alive = 73)
Increased 51/91 (56.0%) 38/53 (71.7%) 13/38 (34.2%)
15.09 0.00Normal 34/91 (37.4%) 11/53 (20.8%) 23/38 (60.5%)
Decreased 6/91 (6.6%) 4/53 (7.5%) 2/38 (5.3%)
Blood pressure (systolic) (normal range: 90 to 120 mmHg) (n = 168; dead = 95; alive = 73)
Hypertensive crisis 7/168 (4.2%) 7/95 (7.4%) 0/73 (0.0%)
7.42 0.06
Increased 78/168 (46.4%) 39/95 (41.0%) 39/73 (53.4%)
Normal 50/168 (29.7%) 28/95 (29.5%) 22/73 (30.1%)
Decreased 33/168 (19.7%) 21/95 (22.1%) 12/73 (16.5%)
Blood pressure (diastolic) (normal range: 60 to 80 mmHg) (n = 168; dead = 95; alive = 73)
Hypertensive crisis 7/168 (4.2%) 7/95 (7.3%) 0/73 (0.0%)
18.97 0.00
Increased 40/168 (23.8%) 22/95 (23.2%) 18/73 (24.7%)
Normal 100/168 (59.5%) 47/95 (49.5%) 53/73 (72.6%)
Decreased 21/168 (12.5%) 19/95 (20.0%) 2/73 (2.7%)
Saturation of O2 (SpO2%) (normal range: 95 to 100) (n = 168; dead = 95; alive = 73)
95 to 100 33/168 (19.6%) 9/95 (9.5%) 24/73 (32.8%)
33.88 1.813e-05
90 to 94 25/168 (14.8%) 7/95 (7.4%) 18/73 (24.6%)
85 to 89 34/168 (20.2%) 26/95 (27.3%) 8/73 (11.0%)
75 to 84 23/168 (13.8%) 15/95 (15.8%) 8/73 (11.0%)
65 to 74 19/168 (11.3%) 11/95 (11.6%) 8/73 (11.0%)
55 to 64 19/168 (11.3%) 16/95 (16.8%) 3/73 (4.1%)
< 55 15/168 (9.0%) 11/95 (11.6%) 4/73 (5.5%)
Acute respiratory distress syndrome (ARDS) (n = 168; dead = 95; alive = 73)
Severe 133/168 (79.2%) 83/95 (87.4%) 50/73 (68.5%)
9.79 0.00
Moderate 31/168 (18.5%) 12/95 (12.6%) 19/73 (26.0%)
Mild 3/168 (1.7%) 0/95 (0.0%) 3/73 (4.1%)
None 1/168 (0.6%) 0/95 (0.0%) 1/73 (1.4%)
* Number of patients with available information; ICU: Intensive care unit; n: number of patients.
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Discussion
On 22nd September 2020, COVID-19 cases in Bangladesh 
totalled to 352,178, with 260,790 recovered cases and 5,007 
deaths. The information on the clinical characteristics of 
COVID-19 individuals having an advanced and deleterious 
prognosis of COVID-19 is still scarce although the positive 
cases are nowhere near decreasing. The median age of 
the critical COVID-19 patients of the sample in this study 
(56 years) is lower than that of Italy, the United States of 
America (USA), Greece and China [22, 27-29]. However, 
the gender propensity of this study’s patients (mostly men) 
is consistent with that of COVID-19 patients in ICUs in 
Italy, USA and China [27-29]. The management of patients 
with several comorbidities is challenging due to their frailty 
and increased risk of mortality, which is amplified when 
these comorbid individuals are diagnosed with COVID-19. 
The current study has found that older (≥ 50) Bangladeshi 
male patients with previous comorbidities, such as diabetes, 
hypertension and heart diseases, are profoundly susceptible 
to COVID-19, which is comparative to the pattern that has 
been revealed in China, Italy and New York [8, 27, 29, 30]. 
In Bangladesh, most people diagnosed with diabetes are 
from urban areas, and the prevalence of diabetes is highest 
among those aged from 55 to 59 years [31]. The presence 
of comorbidity might explain COVID-19’s severity in 
Bangladeshi patients aged 51 to 60 years.
Another finding from this study was that patients with 
asthma survived well compared to other comorbidities. 
As with other viruses, SARS-CoV-2 triggers asthma 
exacerbations, which is why asthma is listed as a risk factor 
for COVID-19 related morbidity. However, this study’s 
finding is consistent with that of Leonardo Antonicelli et 
al. (2020), who found that asthma seems to play a minimal 
role in clinical severity [32]. ARDS (79.2%) was found to 
be the most prominent symptom within the study sample 
upon admission to the ICU, and this was also reflected 
in patients described in reports from China, USA and 
Europe [8, 27, 28]. Other noteworthy symptoms are fever 
(8.40%) and coughing (7.70%), and the results obtained by 
this study align with the trends concerning high prevalence 
seen in other countries  [27-29]. Intestinal signs and 
symptoms, such as diarrhoea, were rarely developed by the 
patients in this study. 
Tab. III. Laboratory findings of patients with COVID-19 in ICUs.








White blood cell count (× 109 per L; normal range 4-10) (n* = 61; dead* = 32; alive* = 29)
Increased 42/61 (68.9%) 22/32 (68.8%) 20/29 (69.0%)
0.15 0.93Normal 14/61 (23.0%) 7/32 (21.9%) 7/29 (24.1%)
Decreased 5/61 (8.2%) 3/32 (9.4%) 2/29 (6.9%)
Haemoglobin (g/L; normal range 130-175) (n* = 57; dead* = 28; alive* = 29
Increased 7/57 (12.3%) 2/28 (7.1%) 5/29 (17.2%)
1.82 0.40Normal 33/57 (57.9%) 16/28 (57.1%) 17/29 (58.6%)
Decreased 17/57 (29.8%) 10/28 (35.7%) 7/29 (24.1%)
Neutrophils (× 109 per L; normal range 1.8-6.3) (n* = 66; dead* = 27; alive* = 39)
Increased 44/66 (66.7%) 18/27 (66.7%) 26/39 (66.7%)
0.28 0.87Normal 16/66 (24.2%) 6/27 (22.2%) 10/39 (25.6%)
Decreased 6/66 (9.1%) 3/27 (11.1%) 3/39 (7.7%)
Lymphocytes (× 109 per L; normal range 1.1-3.2) (n* = 48; dead* = 19; alive* = 29)
Increased 16/48 (33.3%) 5/19 (26.3%) 11/29 (37.9%)
1.27 0.53Normal 23/48 (47.9%) 11/19 (57.9%) 12/29 (41.4%)
Decreased 9/48 (18.8%) 3/19 (15.8%) 6/29 (20.7%)
Platelets (× 109 per L; normal range 125-350) (n* = 57; dead* = 28; alive* = 29)
Increased 18/57 (31.6%) 7/28 (25.0%) 11/29 (37.9%)
1.20 0.55Normal 25/57 (43.9%) 13/28 (46.4%) 12/29 (41.4%)
Decreased 14/57 (24.6%) 8/28 (28.6%) 6/29 (20.7%)
D-dimer (mg/L; normal range < 0.5) (n* = 71; dead* = 31; alive* = 40)
Normal 22/71 (31.0%) 8/31 (25.8%) 14/40 (35.0%)
2.4 0.48
> 0.5 to ≤ 5 34/71 (47.9%) 16/31 (51.6%) 18/40 (45.0%)
> 5 to ≤ 10 11/71 (15.5%) 4/31 (12.9%) 7/40 (17.5%)
> 10 4/71 (5.6%) 3/31 (9.7%) 1/40 (2.5%)
Ferritin concentration (μg/L; normal range < 500) (n* = 69; dead* = 30; alive* = 39)
Normal 16/69 (23.2%) 7/30 (23.3%) 9/39 (28.1%)
1.65 0.80
≥ 500 to < 1,000 25/69 (36.2%) 13/30 (43.3%) 12/39 (30.8%)
≥ 1,000 to < 1,500 13/69 (18.8%) 5/30 (16.7%) 8/39 (20.5%)
≥ 1,500 to < 2,000 11/69 (15.9%) 4/30 (13.3%) 7/39 (17.9%)
≥ 2,000 4/69 (5.8%) 1/30 (3.3%) 3/39 (7.7%)
* Number of patients with available information; ICU: Intensive care unit; n: number of patients.
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Tab. IV. Managements of patients with COVID-19 in ICUs.








Respiratory support (n* = 159; dead* = 86; alive* = 73)
Oxygen delivery by mask 103/159 (64.8%) 50/86 (58.1%) 53/73 (72.6%)
8.69
0.03
High-flow nasal cannula 40/159 (25.2%) 28/86 (32.6%) 12/73 (16.4%)
Oxygen delivery by nasal cannula 12/159 (7.5%) 5/86 (5.8%) 7/73 (9.6%)
Non-invasive mechanical ventilation 3/159 (1.9%) 3/86 (3.5%) 0/73 (0.0%)
Invasive mechanical ventilation 0/159 (0.0%) 0/86 (0.0%) 0/73 (0.0%)
Extracorporeal membrane oxygenation 
(ECMO)
0/159 (0.0%) 0/86 (0.0%) 0/73 (0.0%)
None 1/159 (0.6%) 0/86 (0.0%) 1/73 (1.4%)
Oxygen supply (n* = 159; dead* = 86; alive* = 73)
< 2 L min−1 2/159 (1.3%) 0/86 (0.0%) 2/73 (2.7%) 132.32 2.2e-16
> 2 to < 5 L min−1 17/159 (10.7%) 9/86 (10.5%) 8/73 (11.0%)
> 5 to < 10 L min−1 34/159 (21.4%) 17/86 (19.8%) 17/73 (23.3%)
> 10 to < 20 L min−1 97/159 (61%) 53/86 (61.6%) 44/73 (60.3%)
> 20 to < 30 L min−1 1/159 (0.6%) 1/86 (1.2%) 0/73 (0.0%)
> 30 to < 50 L min−1 5/159 (3.1%) 5/86 (5.8%) 0/73 (0.0%)
> 50 to < 70 L min−1 2/159 (1.3%) 1/86 (1.2%) 1/73 (1.4%)
> 70 L min−1 0/159 (0.0%) 0/86 (0.0%) 0/73 (0.0%)
None 1/159 (0.6%) 0/86 (0.0%) 1/73 (1.4%)
Prone position (n = 168; dead = 95; alive = 73)
Yes 151/168 (89.9%) 86/95 (90.5%) 65/73 (89.0%) 0.10 0.75
No 17/168 (10.1%) 9/95 (9.5%) 8/73 (11.0%)
Plasma transfusion (n = 168; dead = 95; alive = 73)
Yes 8/168 (4.8%) 5/95 (5.3%) 3/73 (4.1%) 0.12 0.73
No 160/168 (95.2%) 90/95 (94.7%) 70/73 (95.9%)
Antivirus drugs (n = 168; dead = 95; alive = 73)
Yes 94/168 (56.0%) 56/95 (58.9%) 38/73 (52.1%) 0.80 0.37
No 74/168 (44.0%) 39/95 (41.1%) 35/73 (47.9%)
Antibacterial drugs (n = 168; dead = 95; alive = 73)
Yes 164/168 (97.6%) 95/95 (100.0%) 69/73 (94.5%) 5.33 0.02
No 4/168 (2.4%) 0/95 (0.0%) 4/73 (5.5%)
Anti-allergic drugs (n = 168; dead = 95; alive = 73)
Yes 126/168 (75.0%) 69/95 (72.6%) 57/73 (78.1%) 0.65 0.42
No 42/168 (25.0%) 26/95 (27.4%) 16/73 (21.9%)
Antiemetic drugs (n = 168; dead = 95; alive = 73)
Yes 12/168 (7.1%) 7/95 (7.4%) 5/73 (6.8%) 0.02 0.90
No 156/168 (92.9%) 88/95 (92.6%) 68/73 (93.2%)
Vitamin and mineral supplements (n = 168; dead = 95; alive = 73)
Yes 145/168 (86.3%) 90/95 (94.7%) 55/73 (75.3%) 13.14 0.00
No 23/168 (13.7%) 5/95 (5.3%) 18/73 (24.7%)
Hypertension related drugs (n = 168; dead = 95; alive = 73)
Yes 65/168 (38.7%) 38/95 (40.0%) 27/73 (37.0%) 0.16 0.70
No 103/168 (61.3%) 57/95 (60.0%) 46/73 (63.0%)
Atypical neuroleptic/Anti-psychotic drugs (n = 168; dead = 95; alive = 73)
Yes 6/168 (3.6%) 5/95 (5.3%) 1/73 (1.4%) 1.82 0.18
No 162/168 (96.4%) 90/95 (94.7%) 72/73 (98.6%)
Anti-inflammatory drugs (n = 168; dead = 95; alive = 73)
Yes 149/168 (88.7%) 87/95 (91.6%) 62/73 (84.9%) 1.82 0.18
No 19/168 (11.3%) 8/95 (8.4%) 11/73 (15.1%)
Sedatives (n = 168; dead = 95; alive = 73)
Yes 14/168 (8.3%) 6/95 (6.3%) 8/73 (11.0%) 1.17 0.28
No 154/168 (91.7%) 89/95 (93.7%) 65/73 (89.9%)
Heart disease related drugs (n = 168; dead = 95; alive = 73)
Yes 18/168 (10.7%) 10/95 (10.5%) 8/73 (11.0%) 0.01 0.93
No 150/168 (89.3%) 85/95 (89.5%) 65/73 (89.0%)
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Bronchodilator (n = 168; dead = 95; alive = 73)
Yes 130/168 (77.4%) 76/95 (80.0%) 54/73 (74.0%) 0.86 0.35
No 38/168 (22.6%) 19/95 (20.0%) 19/73 (26.0%)
Anti-ulcerent medications (n = 168; dead = 95; alive = 73)
Yes 143/168 (85.1%) 81/95 (85.3%) 62/73 (84.9%) 0.00 0.95
No 25/168 (14.9%) 14/95 (14.7%) 11/73 (15.1%)
Thyroid and hormone-related drugs (n = 168; dead = 95; alive = 73)
Yes 5/168 (3.0%) 2/95 (2.1%) 3/73 (4.1%) 0.57 0.45
No 163/168 (97.0%) 93/95 (97.9%) 70/73 (95.9%)
* Number of patients with available information; ICU: Intensive care unit; n: number of patients.
Fig. 3. Drugs, vitamins and electrolytes commonly administered to COVID-19 patients in the ICU. (A) Different generics of the drugs ad-
minister to COVID-19 patients in the ICU; (B) Venn diagram of drug combinations for the commonly used antibiotic, Meropenem with two 
antiviral drugs and two glucocorticoids, with the antiviral drugs being Favipiravir and Remdesivir and the glucocorticoids being Methylpred-
nisolone and Dexamethasone and the proportions of dead and alive patients in each overlapped drug group being shown as a percentage; 
(C) Pie chart illustrating the numerical proportion of dead and alive patients who took Vitamin C, Vitamin D and Zinc supplements. 
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Majority of the study population had to rely upon 
supplemental oxygen while being cared for in the ICU. 
The cause of their inclination towards supplemental 
oxygen was severe to moderate ARDS which was 
indicated by their low oxygen saturation levels. In cases 
with depleting oxygen saturation, Oxygen therapy by high-
flow nasal cannula (HFNC) and mechanical ventilators 
provide higher efficacy in the matter of additional oxygen 
support [33, 34]. However, given the spike in COVID-19 
cases, the demand of HFNC has increased substantially 
because HFNC has been found to improve therapy by 
reducing the requirement of invasive ventilation  [33]. 
Unfortunately, during the initial stages of this study HFNC 
could not be provided to the participating population and 
ventilators were limited as well which deprived patients of 
the support of mechanical ventilation when needed. This 
scarcity of proper ventilation might explain the prevalence 
of a high mortality rate in patients with a moderate to high 
fever and a low oxygen saturation. 
Therapeutic plasma exchange has been recommended as 
a treatment measure for patients with severe COVID-19; 
however, this study found that therapeutic plasma 
exchange had no significant impact on the improvement 
of critically ill patients. According to a recent study, 
therapeutic plasma exchange can be effective in critically 
ill patients if it can be applied within the first week of 
symptom onset [35]. Unfortunately, most of the patients 
in the current study were admitted to the ICU in a critical 
condition due to the lack of available ICU beds. Therefore, 
it may have been too late for convalescent plasma therapy 
to have an effective impact.
To the extent of the author’s knowledge, so far, this study 
is the only study on the medicine administered to critically 
ill COVID-19 patients in Bangladesh. Currently, there is no 
recommended treatment for COVID-19 infection in careful 
supportive care [36]. In this study, 97.6% of patients received 
antibacterial agents, 56% received antiviral therapy and 
88.7% received anti-inflammatory drugs. Even though the 
antiviral drug Favipiravir was the mostly used antiviral drug, 
the survival rate was higher among the patients who had 
been given Remdesivir. Favipiravir concentrations become 
lower in critically ill patients than in healthy subjects, which 
might be one reason why Favipiravir is less effective [37]. 
Several countries, such as Japan, Taiwan and USA, and 
the European Union (EU) suggest the conditional use of 
Remdesivir to treat critical patients  [38,  39]. Therefore, 
Remdesivir can be a better choice over Favipiravir in 
providing aid to COVID-19 individuals. 
A recent report suggests that glucocorticoids may also 
minimize severe clinical outcomes in critical COVID-19 
patients with ARDS  [40]. The current study finds 
that Dexamethasone has comparatively better clinical 
outcomes than Methylprednisolone. According to a large 
clinical trial conducted in the United Kingdom (UK), 
Dexamethasone reduced deaths by about one-third in 
critical COVID-19 patients who were on ventilator 
support [41]. In this study, only one out of six patients who 
were treated with both Remdesivir and Dexamethasone 
died. However, further studies with larger sample sizes are 
required to evaluate the effectiveness of the combined use 
of Remdesivir and Dexamethasone.
Although the findings of this study were significant, 
limitations were also in order. Firstly, laboratory data 
collection to conduct a broad and extensive study was 
inevitably challenging as the laboratory results were not 
systematically collected. Secondly, the evaluated data was 
extracted retrospectively from patients’ medical files and 
not all laboratory tests were conducted on all patients. 
Thirdly, because of the study’s objective to identify the 
critical care needs of patients with the greatest severity 
of illness, the sample size is small. Therefore, more 
thorough assessment of comorbidities in larger samples of 
critical Bangladeshi patients with COVID-19 and future 
studies are required. Despite these limitations, this study 
represented the largest cohort of critically ill COVID-19 
patients from Bangladesh reported to date.
Conclusions
To summarize, parallel to the data obtained from studies 
conducted in other countries, there is an elevated prevalence 
of comorbidities, such as diabetes, hypertension and heart 
diseases, in a profuse number of COVID-19 patients with 
critical expositions who are hospitalised in Bangladesh. 
Since this cohort is more vulnerable in terms of COVID-19 
related morbidity and mortality, besides implementing an 
effective policy for the prevention and control of the disease 
in general, the authorities should pay more attention to 
these atypical patients. In conclusion, the findings reported 
here provide important context for effective strategies for 
the provision of comprehensive health care to critically ill 
COVID-19 patients. However, future studies with larger 
sample sizes are needed in order to assess the risk factors 
and associated clinical outcomes in a broader sense. 
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